Additionally, FGL1 appears to be an atypical biomarker for nonalcoholic fatty liver disease, type 2 diabetes and obesity, and is involved in regulation of adipogenesis, gluconeogenesis, and insulin resistance through diverse molecular mechanisms 9. This evidence concerns the gene FGL1 and metabolic dysfunction-associated steatotic liver disease.